Hubei Bio-pharmaceutical Industrial Technological Institute Inc.
Clinical trials sponsored by Hubei Bio-pharmaceutical Industrial Technological Institute Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New ointment could zap Sun-Damaged skin lesions Results expected Dec 2026 (estimated)
- Healthy volunteers to test experimental lung disease drug Results expected Dec 2026 (estimated)
- New IPF drug candidate enters first human safety trial Results expected Jan 2027 (estimated)
- Can a new oral drug pass its first safety test in humans? Results expected May 2027 (estimated)
-
Can an experimental pill slow advanced solid tumors? a phase 1 trial puts HW221043 to the test.
Disease control Recruiting nowThis early-stage trial is testing an experimental oral drug called HW221043 in adults with advanced solid tumors who have no standard treatment options left. The study has two parts: first, finding a safe dose, then expanding to see if the drug can shrink tumors or slow their gro…
Phase 1 • Sponsor: Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New ointment for Sun-Damaged skin spots enters early human testing
Symptom relief Recruiting nowThis early-stage study tests an experimental ointment called HW211026 in 40 adults with actinic keratosis, a common skin condition caused by sun damage. The main goal is to check if the ointment is safe and how the body absorbs it. Participants will apply the ointment once or sev…
Phase 1 • Sponsor: Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 08:08 UTC
-
Can a new oral drug pass its first safety test in humans?
Knowledge-focused Recruiting nowThis early-stage trial is testing whether an experimental drug called HW243040 is safe and tolerable in healthy adults aged 18 to 55. Participants receive either the drug or a placebo, and researchers monitor for side effects and how the drug moves through the body. The goal is t…
Phase 1 • Sponsor: Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. • Aim: Knowledge-focused
Last updated Aug 29, 2026 00:00 UTC
-
New drug for lung scarring takes first step in healthy volunteers
Knowledge-focused Recruiting nowThis study is an early safety check for a new drug called HW241045, which may one day help treat a lung disease called IPF. Researchers are giving a single dose to 56 healthy adults to see if it is safe and how the body processes it. No treatment benefit is expected for participa…
Phase 1 • Sponsor: Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC